GSK's RSV Vaccine Approved for Japanese Patients in Their 50s

MT NewswiresNov 22 07:05 ET

Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan

GSK PlcNov 22 00:00 ET

Optimism Over Global Healthcare Sector Rises: Jefferies

Seeking AlphaNov 21 13:45 ET

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board With Appointments of World Class Veterans

PR NewswireNov 21 03:30 ET

CDC Warns Against a Spike in COVID, Flu Cases

Seeking AlphaNov 20 15:17 ET

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study

Zacks Nov 20 10:30 ET